Seres Therapeutics (MCRB) Tops Q3 EPS by 9c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
November 5, 2019 7:00 AM ESTTwo late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020
Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq:... More
